Optical Device Rapidly Detects Biomarkers in Urine
By LabMedica International staff writers Posted on 22 Mar 2016 |

Image: Schematic diagram of the MZI biosensor system for miRNA detection. (a)TEM image of the cross section of a silicon nitride slot wave guide; SEM images of (b) a strip-slot wave guide mode converter and (c) a silicon nitride grating coupler. (d) Image of MZI biosensor platform (Photo courtesy of Agency for Science, Technology and Research).
A compact optical device has been developed that can rapidly and sensitively detect biomarkers in urine and has promise for developing simple point-of-care diagnostics of cancer and other diseases.
Micro ribonucleic acids (miRNAs) are a newly discovered class of short, about 19 to 24 nucleotides in length, fragments of noncoding RNAs that are useful biomarkers for diagnosing various diseases, including cardiac disease and some cancers. Since they are surprisingly well preserved in fluids such as urine and blood, their detection is well suited to a rapid, point-of-care method.
Bioengineers at the Agency for Science, Technology and Research (Singapore) have devised a silicon photonic biosensor that can detect tiny changes in the phase of a light beam caused by hybridization between an immobilized DNA probe and target miRNAs in a sample. A laser beam travels through a waveguide, which splits into two arms: a sensing arm in which the light interacts with the sample and a reference arm. The two light beams then rejoin each other. Binding between the DNA probe and the target miRNA alters the phase of the light traveling in the sensing arm, whereas the phase in the reference arm remains unchanged. The amount of target miRNA in the sample can be determined by monitoring the variation in the intensity of the output beam.
To demonstrate the system, the team used it to detect two types of miRNAs in urine samples from three patients with late-stage bladder cancer; the tests involved a single reaction and took 15 minutes. The microRNA levels of the patients differed markedly from those of two healthy subjects. Mach–Zehnder interferometer (MZI) biosensor was fabricated using standard complementary metal-oxide-semiconductor (CMOS) processes. For the optical characterization of the MZI sensor, the light coming from a TSL-510 tunable laser (Santec; Komaki, Japan) at a wavelength 1,562 nm passes through a polarization controller and a fiber pigtailed collimator.
Mi Kyoung Park, PhD, the principal investigator, said, “Existing methods to detect microRNAs are time consuming and require cumbersome machines, which limit their usefulness in clinical settings. This inspired us to develop a simple and efficient point-of-care device for detecting microRNAs. The device is also highly sensitive and thus does not require labeling or amplification; it can deliver results within 15 minutes, eliminating the need for patients to return for their results; and it can potentially detect up to 16 targets in a single test.” The study was originally published in the September 2015 issue of the journal Biosensors and Bioelectronics.
Related Links:
Agency for Science, Technology and Research
Santec
Micro ribonucleic acids (miRNAs) are a newly discovered class of short, about 19 to 24 nucleotides in length, fragments of noncoding RNAs that are useful biomarkers for diagnosing various diseases, including cardiac disease and some cancers. Since they are surprisingly well preserved in fluids such as urine and blood, their detection is well suited to a rapid, point-of-care method.
Bioengineers at the Agency for Science, Technology and Research (Singapore) have devised a silicon photonic biosensor that can detect tiny changes in the phase of a light beam caused by hybridization between an immobilized DNA probe and target miRNAs in a sample. A laser beam travels through a waveguide, which splits into two arms: a sensing arm in which the light interacts with the sample and a reference arm. The two light beams then rejoin each other. Binding between the DNA probe and the target miRNA alters the phase of the light traveling in the sensing arm, whereas the phase in the reference arm remains unchanged. The amount of target miRNA in the sample can be determined by monitoring the variation in the intensity of the output beam.
To demonstrate the system, the team used it to detect two types of miRNAs in urine samples from three patients with late-stage bladder cancer; the tests involved a single reaction and took 15 minutes. The microRNA levels of the patients differed markedly from those of two healthy subjects. Mach–Zehnder interferometer (MZI) biosensor was fabricated using standard complementary metal-oxide-semiconductor (CMOS) processes. For the optical characterization of the MZI sensor, the light coming from a TSL-510 tunable laser (Santec; Komaki, Japan) at a wavelength 1,562 nm passes through a polarization controller and a fiber pigtailed collimator.
Mi Kyoung Park, PhD, the principal investigator, said, “Existing methods to detect microRNAs are time consuming and require cumbersome machines, which limit their usefulness in clinical settings. This inspired us to develop a simple and efficient point-of-care device for detecting microRNAs. The device is also highly sensitive and thus does not require labeling or amplification; it can deliver results within 15 minutes, eliminating the need for patients to return for their results; and it can potentially detect up to 16 targets in a single test.” The study was originally published in the September 2015 issue of the journal Biosensors and Bioelectronics.
Related Links:
Agency for Science, Technology and Research
Santec
Latest Technology News
- Smartphones Could Diagnose Diseases Using Infrared Scans
- Novel Sensor Technology to Enable Early Diagnoses of Metabolic and Cardiovascular Disorders
- 3D Printing Breakthrough Enables Large Scale Development of Tiny Microfluidic Devices
- POC Paper-Based Sensor Platform to Transform Cardiac Diagnostics
- Study Explores Impact of POC Testing on Future of Diagnostics
- Low-Cost, Fast Response Sensor Enables Early and Accurate Detection of Lung Cancer
- Nanotechnology For Cervical Cancer Diagnosis Could Replace Invasive Pap Smears
- Lab-On-Chip Platform to Expedite Cancer Diagnoses
- Biosensing Platform Simultaneously Detects Vitamin C and SARS-CoV-2
- New Lens Method Analyzes Tears for Early Disease Detection
- FET-Based Sensors Pave Way for Portable Diagnostic Devices Capable of Detecting Multiple Diseases
- Paper-Based Biosensor System to Detect Glucose Using Sweat Could Revolutionize Diabetes Management
- First AI-Powered Blood Test Identifies Patients in Earliest Stage of Breast Cancer
- Optical Biosensor Rapidly Detects Monkeypox Virus at Point of Care
- Nanomaterial-Based Diagnostic Technology Accurately Monitors Drug Therapy in Epilepsy Patients
- New Noninvasive Methods Detect Lead Exposure Faster, Easier and More Accurately at POC
Channels
Clinical Chemistry
view channel
Carbon Nanotubes Help Build Highly Accurate Sensors for Continuous Health Monitoring
Current sensors can measure various health indicators, such as blood glucose levels, in the body. However, there is a need to develop more accurate and sensitive sensor materials that can detect lower... Read more
Paper-Based Device Boosts HIV Test Accuracy from Dried Blood Samples
In regions where access to clinics for routine blood tests presents financial and logistical obstacles, HIV patients are increasingly able to collect and send a drop of blood using paper-based devices... Read moreMolecular Diagnostics
view channel
Highly Accurate Blood Test Diagnoses Alzheimer’s and Measures Dementia Progression
Several blood tests are currently available to assist doctors in diagnosing Alzheimer's disease in individuals experiencing cognitive symptoms. However, these tests do not provide insights into the clinical... Read more
Simple DNA PCR-Based Lab Test to Enable Personalized Treatment of Bacterial Vaginosis
Approximately one in three women aged 14-49 in the United States will experience bacterial vaginosis (BV), a vaginal bacterial imbalance, at some point in their lives. Around 50% of BV cases do not present... Read moreHematology
view channel
New Scoring System Predicts Risk of Developing Cancer from Common Blood Disorder
Clonal cytopenia of undetermined significance (CCUS) is a blood disorder commonly found in older adults, characterized by mutations in blood cells and a low blood count, but without any obvious cause or... Read more
Non-Invasive Prenatal Test for Fetal RhD Status Demonstrates 100% Accuracy
In the United States, approximately 15% of pregnant individuals are RhD-negative. However, in about 40% of these cases, the fetus is also RhD-negative, making the administration of RhoGAM unnecessary.... Read moreImmunology
view channel
Post-Treatment Blood Test Could Inform Future Cancer Therapy Decisions
In the ongoing advancement of personalized medicine, a new study has provided evidence supporting the use of a tool that detects cancer-derived molecules in the blood of lung cancer patients years after... Read moreCerebrospinal Fluid Test Predicts Dangerous Side Effect of Cancer Treatment
In recent years, cancer immunotherapy has emerged as a promising approach where the patient's immune system is harnessed to fight cancer. One form of immunotherapy, called CAR-T-cell therapy, involves... Read more
New Test Measures Preterm Infant Immunity Using Only Two Drops of Blood
Preterm infants are particularly vulnerable due to their organs still undergoing development, which can lead to difficulties in breathing, eating, and regulating body temperature. This is especially true... Read more
Simple Blood Test Could Help Choose Better Treatments for Patients with Recurrent Endometrial Cancer
Endometrial cancer, which develops in the lining of the uterus, is the most prevalent gynecologic cancer in the United States, affecting over 66,000 women annually. Projections indicate that in 2025, around... Read moreMicrobiology
view channel
Breakthrough Diagnostic Technology Identifies Bacterial Infections with Almost 100% Accuracy within Three Hours
Rapid and precise identification of pathogenic microbes in patient samples is essential for the effective treatment of acute infectious diseases, such as sepsis. The fluorescence in situ hybridization... Read moreInnovative ID/AST System to Help Diagnose Infectious Diseases and Combat AMR
Each year, 11 million people across the world die of sepsis out of which 1.3 million deaths are due to antibiotic-resistant bacteria. The burden of antimicrobial resistance (AMR) continues to weigh heavily,... Read more
Gastrointestinal Panel Delivers Rapid Detection of Five Common Bacterial Pathogens for Outpatient Use
Acute infectious gastroenteritis results in approximately 179 million cases each year in the United States, leading to a significant number of outpatient visits and hospitalizations. To address this, a... Read morePathology
view channel
New Laser-Based Method to Accelerate Cancer Diagnosis
Researchers have developed a method to improve cancer diagnostics and other diseases. Collagen, a key structural protein, plays various roles in cell activity. A novel multidisciplinary study published... Read more
New AI Model Predicts Gene Variants’ Effects on Specific Diseases
In recent years, artificial intelligence (AI) has greatly enhanced our ability to identify a vast number of genetic variants in increasingly larger populations. However, up to half of these variants are... Read more
Powerful AI Tool Diagnoses Coeliac Disease from Biopsy Images with Over 97% Accuracy
Coeliac disease is an autoimmune disorder triggered by the consumption of gluten, causing symptoms such as stomach cramps, diarrhea, skin rashes, weight loss, fatigue, and anemia. Due to the wide variation... Read moreIndustry
view channel
Philips and Ibex Expand Partnership to Enhance AI-Enabled Pathology Workflows
Royal Philips (Amsterdam, The Netherlands) has expanded its partnership with Ibex Medical Analytics (Tel Aviv, Israel) and released the new Philips IntelliSite Pathology Solution (PIPS) to further accelerate... Read more
Grifols and Inpeco Partner to Deliver Transfusion Medicine ‘Lab of The Future’
Grifols (Barcelona, Spain), a manufacturer of plasma-derived medicines and innovative diagnostic solutions, has entered into a strategic agreement with Inpeco (Novazzano, Switzerland), a global leader... Read more